Stockscreener 앱 받기
2.52
7.69%
-0.21
시간 외 거래:
2.54
0.02
+0.79%
전일 마감가:
$2.73
열려 있는:
$2.78
하루 거래량:
14.99M
Relative Volume:
1.07
시가총액:
$1.00B
수익:
$241.53M
순이익/손실:
$-389.92M
주가수익비율:
-2.0488
EPS:
-1.23
순현금흐름:
$-323.54M
1주 성능:
-11.58%
1개월 성능:
+18.03%
6개월 성능:
+44.00%
1년 성능:
-67.65%
1일 변동 폭
$2.50
$2.82
1주일 범위
$2.50
$2.885
52주 변동 폭
$1.6385
$7.9747
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
명칭
Iovance Biotherapeutics Inc
전화
(650) 260-7120
주소
825 INDUSTRIAL ROAD, SAN CARLOS
IOVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.52 | 1.08B | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-05-12 | 다운그레이드 | Truist | Buy → Hold |
| 2025-05-09 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-07-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | 개시 | Goldman | Buy |
| 2023-09-18 | 재확인 | Barclays | Overweight |
| 2023-05-30 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | 재개 | Wells Fargo | Equal Weight |
| 2023-01-27 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-31 | 개시 | Guggenheim | Neutral |
| 2022-08-18 | 재개 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-12-07 | 재개 | Cowen | Outperform |
| 2021-06-10 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-05-03 | 개시 | Truist | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2021-03-08 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | 개시 | Mizuho | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-02-26 | 재확인 | Oppenheimer | Outperform |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-10-01 | 개시 | Stifel | Buy |
| 2019-04-29 | 개시 | Piper Jaffray | Overweight |
| 2019-02-28 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-07 | 개시 | Robert W. Baird | Outperform |
| 2018-12-31 | 재개 | B. Riley FBR | Buy |
| 2018-07-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-04-10 | 업그레이드 | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | 재확인 | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-01 | 재확인 | B. Riley FBR, Inc. | Buy |
모두보기
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 7.1%Here's What Happened - MarketBeat
Why Iovance Biotherapeutics Stock Got Mashed on Monday - MSN
Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review - Insider Monkey
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street - Finviz
Will Iovance Biotherapeutics Inc. stock attract more institutional investorsCovered Call Writing & Budget Friendly Investment Plans - bollywoodhelpline.com
Iovance Biotherapeutics: Bright Prospects For 2026 (NASDAQ:IOVA) - Seeking Alpha
The next front against cancer: A Mugglehead roundup - Mugglehead Magazine
Is Iovance (IOVA) Turning Talent Incentives and TIL Optimism Into a Durable Competitive Edge? - Sahm
Iovance Biotherapeutics (IOVA) Stock News Today: Barclays Raises Target, Short-Interest Pressure, and 2026 Catalysts (Dec. 23, 2025) - ts2.tech
Iovance Biotherapeutics: Is it Time to Invest? - StocksToTrade
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 8.7%Still a Buy? - MarketBeat
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4) - marketscreener.com
Will Iovance Biotherapeutics Inc. stock outperform Nasdaq indexTrade Analysis Summary & Community Verified Trade Signals - ulpravda.ru
Iovance Biotherapeutics, Inc. $IOVA Position Increased by Squarepoint Ops LLC - MarketBeat
Aug Drivers: Why retail investors favor Iovance Biotherapeutics Inc. stockEntry Point & Fast Gain Stock Trading Tips - ulpravda.ru
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Why Iovance Biotherapeutics Inc. stock attracts high net worth investors - DonanımHaber
How Iovance Biotherapeutics Inc. (2LB) stock valuation compares with sectorGap Down & Weekly High Return Stock Opportunities - DonanımHaber
Iovance Biotherapeutics (IOVA): Assessing Valuation After FDA Progress, Melanoma Data and Upgraded Analyst Targets - Sahm
Insider Buy: Why retail investors favor Iovance Biotherapeutics Inc. stockJobs Report & Weekly Watchlist of Top Performers - Улправда
Market Trends: Is Iovance Biotherapeutics Inc. (2LB) stock cheap vs fundamentalsMarket Activity Report & Weekly High Return Forecasts - Улправда
There Is A Reason Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Price Is Undemanding - 富途牛牛
Iovance Biotherapeutics (IOVA) Stock News Today (Dec. 18, 2025): Barclays Lifts Target to $10, Analysts Stay Split on Amtagvi’s Launch - ts2.tech
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Barclays Maintains Iovance Biotherapeutics (IOVA) Overweight Recommendation - Nasdaq
Barclays Doubles Iovance Biotherapeutics’ Price Target in Bold Market Move - StocksToTrade
Iovance Biotherapeutics (IOVA) Sees Raised Price Target by Barcl - GuruFocus
Iovance Biotherapeutics Advances Innovative Melanoma Treatment with Updated Study - TipRanks
Barclays’ Bullish Outlook Sparks Iovance Stock Surge - timothysykes.com
Mirador Capital Partners LP Makes New Investment in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.7%Should You Buy? - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Cross Above Fifty Day Moving AverageHere's Why - MarketBeat
What analysts say about Iovance Biotherapeutics Inc 2LB stockLong-Term Investment Plans & Advanced Stock Screening Tools - earlytimes.in
Securities Lawsuit Alert: Iovance Biotherapeutics, Inc. (IOVA)Contact Levi & Korsinsky Before July 14, 2025 - ACCESS Newswire
Iovance Biotherapeutics Stock: Analyzing Its Surprising Surge - StocksToTrade
Will Iovance Biotherapeutics’ Stock Surge? - timothysykes.com
Iovance Biotherapeutics: A Surge or A Signal to Watch? - timothysykes.com
Iovance Biotherapeutics (IOVA): Is the Market Overlooking a Potential Rebound in Valuation After a Tough Year? - Yahoo Finance
Weighing Iovance Biotherapeutics After a 71.8% Slide and DCF Upside in 2025 - Yahoo Finance
Voss Capital LP Acquires New Shares in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
With Iovance Biotherapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
2 Stocks That Could Soar by 52% and 282%, According to Wall Street - Finviz
2 Stocks That Could Soar by 52% and 282%, According to Wall Street - The Motley Fool
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), MBX Biosciences, Inc. (MBX) and Praxis Precision Medicines (PRAX) - The Globe and Mail
What earnings margins imply for Iovance Biotherapeutics Inc. (2LB) stockWeekly Stock Analysis & Fast Momentum Stock Entry Tips - Newser
Why Iovance Biotherapeutics Inc. (2LB) stock benefits from AI revolutionJuly 2025 PostEarnings & Safe Capital Investment Plans - Newser
What technical charts say about Iovance Biotherapeutics Inc. stock2025 Price Action Summary & Reliable Entry Point Trade Alerts - Newser
Will Iovance Biotherapeutics Inc. stock recover faster than peersWeekly Stock Summary & Verified Entry Point Signals - Newser
Iovance Biotherapeutics Inc (IOVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):